These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19261251)

  • 1. Targeting the future in head and neck cancer.
    Brizel DM
    Lancet Oncol; 2009 Mar; 10(3):204-5. PubMed ID: 19261251
    [No Abstract]   [Full Text] [Related]  

  • 2. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
    Cohen EE; Davis DW; Karrison TG; Seiwert TY; Wong SJ; Nattam S; Kozloff MF; Clark JI; Yan DH; Liu W; Pierce C; Dancey JE; Stenson K; Blair E; Dekker A; Vokes EE
    Lancet Oncol; 2009 Mar; 10(3):247-57. PubMed ID: 19201650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage with erlotinib plus bevacizumab: not in NSCLC.
    Sculier JP; Meert AP; Berghmans T
    Lancet; 2011 May; 377(9780):1810-2. PubMed ID: 21621709
    [No Abstract]   [Full Text] [Related]  

  • 4. Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.
    Forastiere AA; Burtness BA
    J Clin Oncol; 2007 Jun; 25(16):2152-5. PubMed ID: 17538157
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck.
    Bhatt VR; Ganti AK
    Oral Oncol; 2013 Aug; 49(8):e25. PubMed ID: 23631847
    [No Abstract]   [Full Text] [Related]  

  • 6. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium.
    Hainsworth JD; Spigel DR; Greco FA; Shipley DL; Peyton J; Rubin M; Stipanov M; Meluch A
    Cancer J; 2011; 17(5):267-72. PubMed ID: 21952273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab.
    Kondo N; Ishiguro Y; Kimura M; Sano D; Fujita K; Sakakibara A; Taguchi T; Toth G; Matsuda H; Tsukuda M
    Oncol Rep; 2008 Aug; 20(2):373-8. PubMed ID: 18636200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
    Herbst RS; Sandler A
    Oncologist; 2008 Nov; 13(11):1166-76. PubMed ID: 18997180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting epidermal growth factor receptor to optimize chemoradiotherapy in locally advanced head and neck cancer: has biology been taken into account?
    Herchenhorn D; Ferreira CG
    J Clin Oncol; 2011 Apr; 29(10):e283-4; author reply e285-7. PubMed ID: 21300921
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
    Siu LL; Soulieres D; Chen EX; Pond GR; Chin SF; Francis P; Harvey L; Klein M; Zhang W; Dancey J; Eisenhauer EA; Winquist E; ;
    J Clin Oncol; 2007 Jun; 25(16):2178-83. PubMed ID: 17538162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer opportunities in systemic therapy of lung cancer.
    Rajan A; Gutierrez M; Giaccone G
    Ann Oncol; 2008 Sep; 19 Suppl 7(Suppl 7):vii31-7. PubMed ID: 18790973
    [No Abstract]   [Full Text] [Related]  

  • 13. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.
    Bozec A; Sudaka A; Fischel JL; Brunstein MC; Etienne-Grimaldi MC; Milano G
    Br J Cancer; 2008 Jul; 99(1):93-9. PubMed ID: 18577994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Head and neck: molecular-targeted therapy].
    Tsukuda M
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1034-9. PubMed ID: 17682304
    [No Abstract]   [Full Text] [Related]  

  • 15. [Role of targeted therapy in the treatment of squamous cell head and neck cancer].
    Gyergyay F
    Magy Onkol; 2007; 51(2):155-7. PubMed ID: 17660872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck.
    Burtness B
    J Clin Oncol; 2005 Aug; 23(24):5440-2. PubMed ID: 16009959
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy for patients with local-regional recurrent or metastatic carcinoma of the head and neck].
    Dufresne A; Gainet M; Stein U; Guardiola E; Pivot X
    Bull Cancer; 2003 Jan; 90(1):39-45. PubMed ID: 12609803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
    Sandler A; Herbst R
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4421s-4425s. PubMed ID: 16857821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
    Fujita K; Sano D; Kimura M; Yamashita Y; Kawakami M; Ishiguro Y; Nishimura G; Matsuda H; Tsukuda M
    Oncol Rep; 2007 Jul; 18(1):47-51. PubMed ID: 17549344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.